Royal college

OPPO Holds 'Design in Tech' Workshop, Interpreting Innovative and Elegant Design Aesthetics of OPPO Products

Retrieved on: 
Friday, September 23, 2022

OPPO Holds 'Design in Tech' Workshop, Interpreting Innovative and Elegant Design Aesthetics of OPPO Products

Key Points: 
  • OPPO Holds 'Design in Tech' Workshop, Interpreting Innovative and Elegant Design Aesthetics of OPPO Products
    Principal of Zaha Hadid Architects, RCA Professor Gather to Discuss the Fusion of Technology and Design
    LONDON, UK - Media OutReach - 23 September 2022 - OPPO presented at the 2022 London Design Festival as the support partner and hosted Design in Tech Workshop interpreting the innovative and elegant design aesthetics of OPPO, and the mission to elevate life through technological artistry.
  • OPPO is committed to connecting technology with people through elegant design and ultimately transforming cutting-edge technology into user-perceivable detail.
  • At the workshop, OPPO Design spokesperson Xi Zeng shared OPPOs persistence in innovative and elegant design and its efforts to break through boundaries.
  • Beyond devices, OPPO also provides its users with ColorOS operating system and internet services such as OPPO Cloud and OPPO+.

Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO

Retrieved on: 
Wednesday, September 21, 2022

Anne Phillips, MD, FRCPC joins Carmots Board and Heather Turner, J.D., joins as Chief Operating Officer.

Key Points: 
  • Anne Phillips, MD, FRCPC joins Carmots Board and Heather Turner, J.D., joins as Chief Operating Officer.
  • We are delighted to welcome Anne Phillips to our Board, said Stig Hansen, PhD, Carmots co-founder and Chief Executive Officer.
  • "I'm also delighted to have Heather Turner join Carmot as COO and member of our executive leadership team, said Stig Hansen.
  • About Carmot Therapeutics, Inc. Carmot Therapeutics (Carmot) is focused on the discovery and development of disease-modifying therapies for patients living with metabolic diseases and cancer.

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

Retrieved on: 
Wednesday, September 14, 2022

RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the companys significant pipeline of development candidates.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the companys significant pipeline of development candidates.
  • Dr. Ryan Arnold has been appointed as the companys new chief medical officer.
  • Dr. Arnold joins Dr. Sheridan and Dr. Helen Thackray, the companys chief research and development officer, as physicians on the companys leadership team.
  • Dr. Sheridan joined BioCryst from Amgen in July 2008 as chief medical officer.

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Retrieved on: 
Wednesday, September 7, 2022

VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the appointment of Doug Williamson to the Company’s Board of Directors (the “Board”). Dr. Williamson will serve on the Compensation, Nominating and Corporate Governance, and Audit Committees as an independent director. Concurrently, Dr. Alan Kozikowski has resigned from the Board.

Key Points: 
  • Dr. Williamson will serve on the Compensation, Nominating and Corporate Governance, and Audit Committees as an independent director.
  • Dr. Williamson has an impressive track record in developing safe and profitable pharmaceuticals and biotechnologies for global industry leaders.
  • With his reputation for generating quality results while improving ROI and building high-performance, engaged teams, we are thrilled to welcome Dr. Williamson to the Board, stated Ian McDonald, CEO and Co-founder of Bright Minds Biosciences.
  • BMB-101 is the subject of a patent licensed by Bright Minds Biosciences from the University of Illinois.

Back-to-school prep: The Canadian Ophthalmological Society urges parents to monitor children's vision to start the school year off right

Retrieved on: 
Tuesday, August 23, 2022

"The start of the school year is always a good time to remember to monitor your child's eyes and determine if they have had any changes to their vision," says Dr. Phil Hooper, President of the Canadian Ophthalmological Society.

Key Points: 
  • "The start of the school year is always a good time to remember to monitor your child's eyes and determine if they have had any changes to their vision," says Dr. Phil Hooper, President of the Canadian Ophthalmological Society.
  • "A comprehensive evaluation early in the school year is important to detect changes and rectify them before they can have an impact on learning."
  • The survey revealed that 83 per cent of respondents believe that prolonged screen time is harmful to their child(ren)'s eye health.
  • The Canadian Ophthalmological Society (COS) is the national, recognized authority on eye and vision care in Canada.

CDR-Life Announces Appointment of Swethajit Biswas, MD, as Chief Medical Officer

Retrieved on: 
Tuesday, August 23, 2022

Prior to joining CDR-Life, Dr. Biswas was a Development Leader for MAGE-A4+ autologous cell therapies at Adaptimmune Therapeutics plc, progressing afamitresgene autoleucel through an accelerated approval submission pathway.

Key Points: 
  • Prior to joining CDR-Life, Dr. Biswas was a Development Leader for MAGE-A4+ autologous cell therapies at Adaptimmune Therapeutics plc, progressing afamitresgene autoleucel through an accelerated approval submission pathway.
  • He also held an academic position as a Clinical Senior Lecturer in medical oncology at Newcastle Universitys Northern Institute for Cancer Research (NICR) from 2009 to 2013.
  • Dr. Biswas received his medical degree from Sheffield University Medical School and his DPhil from the University of Oxford.
  • For more information, please visit cdr-life.com and follow the Company on Twitter and LinkedIn.

Dr. Alika Lafontaine to lead CMA in 2022-23

Retrieved on: 
Sunday, August 21, 2022

TORONTO, Aug. 21, 2022 /CNW/ - Today, Canadian Medical Association (CMA) members and delegates attending the Annual general meeting welcomed Dr. Alika Lafontaine as the organization's 155th President.

Key Points: 
  • TORONTO, Aug. 21, 2022 /CNW/ - Today, Canadian Medical Association (CMA) members and delegates attending the Annual general meeting welcomed Dr. Alika Lafontaine as the organization's 155th President.
  • Dr. Lafontaine becomes the first indigenous President in the organization's history.
  • Born and raised in Treaty 4 Territory (Southern Saskatchewan), Dr. Lafontaine has Metis, Oji-Cree and Pacific Islander ancestry.
  • "As I take on the role of CMA president, I want my fellow physicians to know that I see their struggles and I am deeply committed to making progress toward a better future," says Dr. Lafontaine.

Henry Schein Announces the Passing of Board Member E. Dianne Rekow

Retrieved on: 
Thursday, August 11, 2022

Henry Schein, Inc. (Nasdaq: HSIC) announced the passing today of E. Dianne Rekow, DDS, Ph.D., a member of the Companys Board of Directors since 2014 and a leader in the development of digital dentistry.

Key Points: 
  • Henry Schein, Inc. (Nasdaq: HSIC) announced the passing today of E. Dianne Rekow, DDS, Ph.D., a member of the Companys Board of Directors since 2014 and a leader in the development of digital dentistry.
  • View the full release here: https://www.businesswire.com/news/home/20220811005737/en/
    E. Dianne Rekow, DDS, Ph.D., a member of the Henry Schein Board of Directors since 2014 and a leader in the development of digital dentistry.
  • (Photo: Business Wire)
    Dianne was an extraordinary board member and an internationally known authority on aesthetic and restorative dentistry as well as one of the early pioneers in digital dentistry, said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, Henry Schein, Inc. Diannes contributions to the Henry Schein board have been many and impactful, including serving as a member of our Strategic Advisory Committee.
  • Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology.

HaemaLogiX strengthens Board with appointment of Dr. Geoff Nichol

Retrieved on: 
Thursday, July 7, 2022

Bryce Carmine, HaemaLogiX's Chairman and CEO commented: "Geoff's impressive, globally recognised background in drug development, and in particular, in antibody development, makes him a valuable contribution to the HaemaLogiX board.

Key Points: 
  • Bryce Carmine, HaemaLogiX's Chairman and CEO commented: "Geoff's impressive, globally recognised background in drug development, and in particular, in antibody development, makes him a valuable contribution to the HaemaLogiX board.
  • Importantly, during his time at Medarex, Geoff oversaw the preclinical and clinical development of KappaMab, our multiple myeloma drug candidate.
  • He brings outstanding industry knowledge and a highly translatable skillset to our Board mix.
  • Dr. Nichol brings nearly 30 years' experience in drug development.

Soak up the sun responsibly: The Canadian Ophthalmological Society reminds Canadians to protect their eyes this UV Safety Awareness Month

Retrieved on: 
Wednesday, July 6, 2022

"It's important to protect our eyes from harmful UV rays all year long to decrease the risk of developing cataracts later in life," says Dr. Phil Hooper, President of the Canadian Ophthalmological Society.

Key Points: 
  • "It's important to protect our eyes from harmful UV rays all year long to decrease the risk of developing cataracts later in life," says Dr. Phil Hooper, President of the Canadian Ophthalmological Society.
  • The survey also revealed that younger Canadians may not be taking enough precaution in protecting their eyes from harmful UV rays.
  • An online survey of 2003 Canadians aged 18+ was completed between June 10th and June 21st, 2022, using Leger's online panel.
  • The Canadian Ophthalmological Society (COS) is the national, recognized authority on eye and vision care in Canada.